Regulatory Growing Pains Heat Up Cold Chain
The global issues surrounding shipping and housing hazardous materials and biologic substances can only be compared to the Gordian knot, but unlike Alexander, the parties involved do not have the luxury of a quick and dirty solution.
Biologics companies face a unique paradox. Inconsistent regulations surrounding their intransit products on one hand, and a Byzantine shipping process on the other, result in clinical delays, and ultimately potential financial losses. Air freight is the main culprit. Anecdotal evidence tells of carriers leaving sensitive biologics on the tarmac to avoid warehouse costs. This fuels fears of hazardous products and thousands of dollars in biologic finished goods being stolen or lost in airport black holes.
This is not exactly news. The pharmaceutical industry’s dissatisfaction with air freight has been growing steadily for years. However, some handlers are working to quell those concerns.
Article by Dan Herczak for IQPC.